Across TCGA pan-cancer cohorts, ADH1B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ADH1B data layer compared with 22 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher ADH1B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ADH1B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LIHC, HNSC, and UCEC are the cancer types where ADH1B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.079	0.544	<.001	36	view →
HNSC	OS	Median	III,IV	0.021	0.675	<.001	18	view →
UCEC	DFS	Median	II,III,IV	0.915	0.438	.032	10	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: ADH1B tumor-vs-normal RNA expression · all ADH1B data types